Table 5.
Clinical Characteristics of Studied AML Cases According to Combined CXCR4 Positivity and SDF-1 Gene Polymorphisms
| Clinical data | CXCR4negative and SDF-1 GG (n=17) | CXCR4negative and SDF-1 AG+AA (n=19) |
CXCR4positive and SDF-1 GG (n=15) |
CXCR4positive and SDF-1 AG+AA (n=9) | P* | P^ | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| No | % | No | % | No | % | No | % | |||
| Age | ||||||||||
| Age <60 | 12 | 70.6 | 17 | 89.5 | 14 | 93.3 | 9 | 100 | 0.117 | 0.055 |
| Age ≥60 | 5 | 29.4 | 2 | 10.5 | 1 | 6.7 | 0 | 0 | ||
| TLC x 109/l | ||||||||||
| Median | 33 | 57 | 64 | 31 | 0.391 | 0.296 | ||||
| BM blast cells | ||||||||||
| Median | 90 | 92 | 92 | 95 | 0.382 | 0.219 | ||||
| FAB | ||||||||||
| M1/M2 | 6 | 35.3 | 6 | 31.6 | 4 | 26.7 | 2 | 22.2 | 0.675 | 0.693 |
| M4-5 | 9 | 52.9 | 11 | 57.9 | 11 | 73.3 | 7 | 77.8 | ||
| M7 | 2 | 11.8 | 2 | 10.5 | 0 | 0.0 | 0 | 0 | ||
| Clinical presentation | ||||||||||
| Toxic manifestations (n=34) | 5 | 29.4 | 11 | 57.9 | 10 | 66.7 | 8 | 88.9 | 0.023 | 0.01 |
| EMI (n=51) | 12 | 70.9 | 16 | 84.2 | 15 | 100.0 | 8 | 88.9 | 0.137 | 0.143 |
| Cytogenetics risk stratification | ||||||||||
| Favorable (n=21) | 9 | 53 | 8 | 42.1 | 3 | 20.0 | 1 | 11.2 | 0.099 | 0.174 |
| Intermediate (n=15) | 4 | 23.5 | 5 | 26.3 | 2 | 13.3 | 4 | 44.4 | ||
| Unfavorable (n=24) | 4 | 23.5 | 6 | 31.6 | 10 | 66.7 | 4 | 44.4 | ||
| Response rate | ||||||||||
| CR | 8 | 47.1 | 8 | 42.1 | 0 | 0.0 | 2 | 22.2 | 0.016 | 0.193 |
| Non-CR (ID and RD) | 9 | 52.9 | 11 | 57.9 | 15 | 100 | 7 | 77.8 | ||
P*, significance between 4 groups; p^, significance between CXCR4 negative with SDF-1(G\G) alleles genotype AML patients vs disconcordant vs CXCR4 positive with SDF-1(A) allele carrier genotype AML patients; CR, Complete response; ID, Induction death; RD, Refractory disease; EMI, Extra medullary infiltration.